Research programme: cytokine inhibitors - Transition Therapeutics

Drug Profile

Research programme: cytokine inhibitors - Transition Therapeutics

Alternative Names: Minozac; MW 015188WH; TT302

Latest Information Update: 14 Sep 2016

Price : $50

At a glance

  • Originator Northwestern University
  • Developer Chinese Academy of Sciences; InnovatePharma; Northwestern University; Transition Therapeutics; University of California at Los Angeles
  • Class Pyridazines; Small molecules
  • Mechanism of Action Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Alzheimer's disease; Arthritis

Highest Development Phases

  • No development reported Alzheimer's disease; Rheumatoid arthritis
  • Discontinued Brain injuries; Multiple sclerosis; Parkinson's disease

Most Recent Events

  • 31 Aug 2016 Transition Therapeutics has been acquired by OPKO Health
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top